The American Society of Gene and Cell Therapy’s 2026 Annual Meeting
Boston, MA, USA & Virtual
May 11–15, 2026
Join Genedata experts at the 29th Annual Meeting of ASGCT.
Don't miss the opportunity to see how Genedata Selector® enables biopharmaceutical organizations to make data-driven go/no-go decisions regarding cell and gene therapy products' safety, quality, and integrity with significant time savings. By providing out-of-the-box pipelines for automated NGS data analysis, Genedata empowers scientists to bring NGS assays in-house and in a GMP validated environment without the need for extensive bioinformatics training.
For more information about Genedata solutions or to set up a meeting, please contact us.
Recommended Posters: Exhibit Hall C + B2
Unified In-House Platform for Assay Development and Data Integrity
for GMP‑Ready NGS Analytics
Presenter: Hunter Stamba, Genedata Inc., Boston, MA, USA
Abstract ID: 1231
Cell and gene therapies (CGTs) face challenges such as short shelf life, complex manufacturing, high costs, and stringent component evaluation. Development demands robust CMC and advanced analytics to ensure quality, safety, and regulatory compliance. Next‑generation sequencing (NGS) is central for genetic characterization and biosafety and is increasingly accepted by regulators. Yet outsourcing NGS creates cost and time bottlenecks, while custom pipelines are hard to validate. Genedata Selector® delivers a scalable, validation‑ready, compliant in‑house NGS platform.
Presentation Day: May 12, 2026
Poster Reception Time: 5:00 PM - 6:30 PM
A Unified NGS‑MAM Framework for Comprehensive Vector Characterization
Presenter: Ziwei (Coco) Li, Genedata Inc., Boston, MA, USA
Abstract ID: 3206
Cell and gene therapies are advancing rapidly but require strict control of Critical Quality Attributes (CQAs) such as identity, potency, and safety. Viral vectors like LV and AAV demand precise characterization, while traditional methods are costly and slow. Next‑generation sequencing (NGS) enables comprehensive, high‑resolution CQA assessment but is complex to implement and validate. Genedata Selector® provides a validation‑ready in‑house NGS platform that streamlines bioinformatics workflows and enables multi‑attribute CQA monitoring, reducing costs and accelerating development.
Presentation Day: May 14, 2026
Poster Reception Time: 5:00 PM - 6:30 PM
Automated NGS Data Analysis in AAV Upstream Manufacturing and Producer Cell Line Characterization
Presenter: Thipa Asvarak, Genedata Inc., Boston, MA, USA
Abstract ID: 2138
Ensuring the quality and safety of AAV‑based cell and gene therapies is increasingly critical as demand grows. Regulatory compliance, risk mitigation, and standardized assays across upstream manufacturing are essential. Next‑generation sequencing (NGS) enables comprehensive, accurate, and faster characterization of cell lines and vectors than traditional methods. However, manual handling of complex NGS data limits its value. Robust automation of NGS analysis workflows is therefore essential. Genedata Selector® automates and accelerates in‑house NGS data analysis to support seamless CGT development.
Presentation Day: May 13, 2026
Poster Reception Time: 5:00 PM - 6:30 PM
Poster Sessions:
Date: May 12-14, 2025
Time: 5:00 PM - 6:30 PM
Location: Exhibit Hall C + B2
